Ionis Pharmaceuticals
OverviewSuggest Edit
Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. It provides an antisense technology platform designed to treat complicated and rare diseases. The company offers SPINRAZA, a treatment for children and adults with spinal muscular atrophy (SMA), TEGSEDI, a medicine that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis, and Waylivra, a medicine used to treat familial chylomicronaemia syndrome (FCS).
| Type | Public | |
| Founded | 1989 | |
| HQ | Carlsbad, CA, US | Map |
| Website | ionispharma.com | |
| Employee Ratings | More | |
| Overall Culture | D | More |
Recent NewsAll News
Key People/Management at Ionis Pharmaceuticals
Brett P. Monia
Chief Executive Officer & Director
Onaiza Cadoret-Manier
Executive Vice President, Chief Corporate Development and Commercial Officer
C. Frank Bennett
Executive Vice President, Chief Scientific Officer
Eric E. Swayze
Executive Vice President, Research
Patrick R. O'Neil
Executive Vice President, Legal & General Counsel, Chief Compliance Officer
Richard S. Geary
Executive Vice President, Chief Development Officer
Ionis Pharmaceuticals Office Locations
Ionis Pharmaceuticals has an office in Carlsbad
Carlsbad, CA, US (HQ)
2855 Gazelle Ct
Ionis Pharmaceuticals Financials and Metrics
Ionis Pharmaceuticals Revenue
Ionis Pharmaceuticals's revenue was reported to be $729.26 m in FY, 2020 which is a 35% decrease from the previous period.
| USD | |
|---|---|
Revenue (Q1, 2021) | 111.6m |
Gross profit (Q1, 2021) | 109.0m |
Gross profit margin (Q1, 2021), % | 97.7% |
Net income (Q1, 2021) | (89.9m) |
EBIT (Q1, 2021) | (92.0m) |
Market capitalization (9-Sept-2021) | 5.1b |
Closing stock price (9-Sept-2021) | 36.3 |
Cash (31-Mar-2021) | 414.2m |
EV | 4.8b |
Ionis Pharmaceuticals's current market capitalization is $5.1 b.
Annual
Annual
Annual
Quarterly
| USD | FY, 2018 |
|---|---|
EV/EBIT | -127.2 x |
EV/CFO | 12.9 x |
Revenue/Employee | 1.1m |
Debt/Equity | 0.5 x |
Debt/Assets | 0.2 x |
Financial Leverage | 2.2 x |
P/E Ratio | 26.1 |
Ionis Pharmaceuticals Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Akcea Therapeutics | August 31, 2020 | $500 m |
| Akcea Securities Corporation | ||
| Akcea Therapeutics Canada Inc | ||
| Akcea Therapeutics France SAS | ||
| Akcea Therapeutics Germany GmbH | ||
| Akcea Therapeutics, Inc | ||
| Akcea Therapeutics Ireland Limited | ||
| Akcea Therapeutics UK Limited | ||
| Ionis Development (Ireland) Limited | ||
| Isis USA Limited |
Ionis Pharmaceuticals Revenue Breakdown
Ionis Pharmaceuticals revenue breakdown by business segment: 80.4% from Ionis Core and 19.6% from Akcea Therapeutics
Ionis Pharmaceuticals Cybersecurity Score
Ionis Pharmaceuticals Online and Social Media Presence
3.53k Twitter followers
Ionis Pharmaceuticals has 3.53k Twitter Followers. The number of followers has increased 0.6% month over month and increased 5.2% quarter over quarter
Ionis Pharmaceuticals's Trends
Twitter Engagement Stats for @ionispharma
1k
Tweets
503
Following
3.5k
Followers
2
Tweets last 30 days
5
Avg. likes per Tweet
100%
Tweets with engagement
Ionis Pharmaceuticals Company Culture
Overall Culture
D
60/100
CEO Rating
C
67/100
Compensation
C+
69/100
Diversity
D
60/100
Ionis Pharmaceuticals News and Updates
August 04, 2021
Ionis Pharmaceuticals : Q2 Earnings Snapshot
Ionis Pharmaceuticals Inc. (IONS) on Wednesday reported a loss of $81 million in its second quarter.
July 13, 2021
Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc (NASDAQ: BCYC) to increase the delivery capabilities of Ionis' advanced LIgand Conjugated Antisense (LICA) medicines.
June 23, 2021
Ionis Pharmaceuticals Stock Looks Attractive At $37
We believe that the stock price of Ionis Pharmaceuticals, a biotech company that specializes in discovering and developing RNA-targeted therapeutics, is undervalued at current levels of under $37. IONS stock is down 11% from the levels of around $42 it was at on March 23, 2020...
June 03, 2021
Ionis Pharmaceuticals (IONS) Names Joseph Loscalzo Chairman, Allene Diaz Appointed Director
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced changes to its board of directors. Joseph Loscalzo, M.D., Ph.D., has been appointed chairman of the board and Allene M. Diaz has been appointed to the board.
May 14, 2021
SVB Leerink Boosts Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $41.00
Ionis Pharmaceuticals (NASDAQ:IONS) had its target price lifted by equities researchers at SVB Leerink from $36.00 to $41.00 in a research note issued on Friday, Benzinga reports. The firm currently has a "market perform" rating on the stock. SVB Leerink's target price points to a potential upside o…
May 07, 2021
Ionis Pharmaceuticals (NASDAQ:IONS) Upgraded at UBS Group
Ionis Pharmaceuticals (NASDAQ:IONS) was upgraded by research analysts at UBS Group from a "sell" rating to a "neutral" rating in a research report issued to clients and investors on Friday, Briefing.com reports. The firm presently has a $37.50 price objective on the stock, up from their previous pri…
Ionis Pharmaceuticals Blogs
August 04, 2021
Ionis reports second quarter 2021 financial results and recent business achievements
Key Phase 3 milestones move tofersen, eplontersen and pelacarsen closer to the market Exclusive license to Bicycle Therapeutics' technology potentially expands LICA technology capabilities Webcast today, August 4, 2021, at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Aug.
August 02, 2021
Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events
Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events
Content Import
Mon, 08/02/2021 - 09:31
Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recur…
July 29, 2021
Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen
Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen
Content Import
Thu, 07/29/2021 - 07:07
Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen
July 29, 2021 at 7:05 AM EDT
This release is a backfill from a News W…
July 26, 2021
Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC
- Phase 1b study of BIIB080/IONIS-MAPT Rx met primary objective of safety and tolerability - Study demonstrated durable, robust, time and dose dependent lowering of tau protein in cerebrospinal fluid CAMBRIDGE, Mass. and CARLSBAD, Calif. , July 26, 2021 /PRNewswire/ -- Biogen Inc.
July 21, 2021
Ionis to hold second quarter 2021 financial results webcast
Ionis to hold second quarter 2021 financial results webcast
Content Import
Wed, 07/21/2021 - 07:05
Ionis to hold second quarter 2021 financial results webcast
July 21, 2021 at 7:05 AM EDT
This release is a backfill from a News Wire
General
…
June 14, 2021
Ionis' Chief Scientific Officer C. Frank Bennett, Ph.D., receives Gabbay Award in Biotechnology and Medicine
- Award recognizes Dr. Bennett's innovative work on antisense therapy CARLSBAD, Calif. , June 14, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that Executive Vice President and Chief Scientific Officer C. Frank Bennett , Ph.D., is a co-recipient of the 23 rd
Ionis Pharmaceuticals Frequently Asked Questions
When was Ionis Pharmaceuticals founded?
Ionis Pharmaceuticals was founded in 1989.
Who are Ionis Pharmaceuticals key executives?
Ionis Pharmaceuticals's key executives are Brett P. Monia, Onaiza Cadoret-Manier and C. Frank Bennett.
How many employees does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 757 employees.
What is Ionis Pharmaceuticals revenue?
Latest Ionis Pharmaceuticals annual revenue is $729.3 m.
What is Ionis Pharmaceuticals revenue per employee?
Latest Ionis Pharmaceuticals revenue per employee is $963.4 k.
Who are Ionis Pharmaceuticals competitors?
Competitors of Ionis Pharmaceuticals include Intellia Therapeutics, Ultragenyx Pharmaceutical and Bluebird Bio.
Where is Ionis Pharmaceuticals headquarters?
Ionis Pharmaceuticals headquarters is located at 2855 Gazelle Ct, Carlsbad.
Where are Ionis Pharmaceuticals offices?
Ionis Pharmaceuticals has an office in Carlsbad.
How many offices does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies